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Objectives: To assess baseline imbalances in placebo‐controlled trials of atypical
antipsychotics in dementia, and their association with neuropsychiatric symptoms
(NPS), extrapyramidal symptoms (EPS), and mortality.
Method: We searched for trials in multiple sources. Two reviewers extracted
baseline characteristics and outcomes per treatment group. We calculated direction,
range, pooled mean, and heterogeneity in the baseline differences, and used meta‐
regression for the relationship with the outcomes.
Results: We identified 23 trials. Baseline type of dementia, cognitive impairment
and NPS were poorly reported. The drug group had a higher mean age than the
placebo group in nine trials and lower mean age in three trials (p = 0.073). The
difference in percentage men between the drug and placebo group ranged from
−9.7% to 4.4%. There were no statistically significant pooled baseline differences,
but heterogeneity was present for age. Higher mean age at baseline in the drug versus
placebo group was significantly associated with greater reduction in NPS, and higher
percentage of non‐White persons with lower risk of EPS. Imbalances were not
significantly associated with risk of mortality.
Conclusion: Randomized trials of atypical antipsychotics in dementia showed base-
line imbalances that were associated with higher efficacy and lower risk of EPS for
atypical antipsychotics versus placebo.
KEYWORDS
antipsychotics, baseline imbalances, bias, meta‐regression, trials1 | INTRODUCTION
Randomization is the cornerstone of clinical trials. Randomization is used
to ensure that chance instead of patient characteristics determine
treatment assignment. In daily medical practice, patient characteristics- - - - - - - - - - - - - - - - - - - - - - - - - - -
the Creative Commons Attribution
ed, the use is non‐commercial and
ods in Psychiatric Research Publiaffect the choice of treatment, andwill therefore be distributed unevenly
across treatment groups. Moreover, these patient characteristics may
also affect prognosis independently of the effect of treatment. Hence,
treatment groups of a trial need to be comparable to establish an
unbiased effect of a treatment on prognosis (clinical outcomes).- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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2 of 10 HULSHOF ET AL.The larger the sample size of a randomized trial is, the smaller the
differences between treatment groups at the start of the trial will
become and the more comparable the groups will be. Yet, imbalanced
groups can occur by chance despite adequately designed and con-
ducted randomization procedures, especially in trials with small sample
sizes. In addition, flawed or corrupted randomization procedures
can give rise to systematic baseline imbalances between groups
(Clark et al., 2014; Hróbjartsson, Boutron, Turner, Altman, & Moher,
2013). If the baseline imbalances are distributed in the sameway across
trials testing the same treatment, they will bias the pooled results of
those trials too (Corbett, Higgins, & Woolacott, 2014; Egger, Juni,
Bartlett, Holenstein, & Sterne, 2003; Luijendijk & Hulshof, 2015; Riley
et al., 2013; Schulz, Chalmers, Hayes, & Altman, 1995; Trowman,
Dumville, Torgerson, & Cranny, 2007).
In a previous meta‐analysis, we observed baseline imbalances in
trials testing antipsychotic drugs in dementia (Hulshof, Zuidema,
Ostelo, & Luijendijk, 2015). Atypical antipsychotic have been found to
reduce neuropsychiatric symptoms (NPS) and to increase the risk of
extrapyramidal symptoms (EPS) and mortality (Schneider, Dagerman,
& Insel, 2005; Ma et al., 2014). In some trials of atypical antipsychotics,
the baseline characteristics of the atypical group seemed unfavorable in
comparison with placebo (Ballard et al., 2005; Street, Clark, Gannon,
Cummings, & Bymaster, 2000; Zhong, Tariot, Mintzer, Minkwitz, &
Devine, 2007): Patients were older, and more often men or diagnosed
with vascular dementia. These factors are predictive of EPS and death
in patients with dementia (Fitzpatrick, Kuller, Lopez, Kawas, & Jagust,
2005; Gambassi et al., 1999; Garcia‐Ptacek et al., 2014; Mitchell
et al., 2004; Rountree, Chan, Pavlik, Darby, & Doody, 2012). Therefore,
not the atypical drugs themselves but the vulnerability of the patients in
the drug compared with the placebo groups could have resulted in a
higher risk of EPS and deaths. Moreover, if the more vulnerable
patients had more severe NPS and dropped out more often, the
remaining group of patients would have had less NPS. Consequently,
the effect of atypical antipsychotics on symptom reduction might have
overestimated (Hernán, Hernández‐Díaz, & Robins, 2004).
Atypical antipsychotics were introduced to the market with the
claim that these drug were as effective as haloperidol but had less side
effects (Allain et al., 2000; De Deyn, Rabheru, & Rasmussen, 1999;
Tariot et al., 2006). At the time, haloperidol—a typical antipsychotic—
was the first choice of treatment for agitation and psychosis in demen-
tia. To substantiate the claim of relative benefits and harms, atypical
antipsychotics and haloperidol have been compared with placebo
simultaneously in a number of trials. We observed that in trials with
an haloperidol group, the atypical antipsychotics groups seemed to be
less vulnerable than the placebo groups (Allain et al., 2000; De Deyn
et al., 1999; Hulshof et al., 2015; Tariot et al., 2006). This imbalance
might have led to overestimation of the effect of atypical antipsy-
chotics on reduction of NPS and underestimation of the risk of EPS
compared with placebo. The variation in baseline imbalances between
atypical drug groups and placebo groups across trials enables an evalu-
ation of the effect that the imbalances might have had on trial results.
The aim of this study was (a) to assess the presence of systematic
baseline imbalances in placebo‐controlled trials of atypical antipsy-
chotics in dementia, and (b) to evaluate the association of baseline
imbalances with reduction of NPS and risk of EPS and mortality.2 | METHODS
2.1 | Literature search and selection
Two reviewers (T. A. H. and H. J. L.) searched trials in four sources. First,
we used the electronic databases Pubmed, Cinahl, and Embase and
entered the strings (“generic name atypical antipsychotic” AND trial)
and (dementia). We had composed a list of all atypical antipsychotics
from the websites of the World Health Organization and the Food and
Drug Administration to this end (US Food and Drug Administration,
2013; World Health Organization, 2013). Second, we hand‐searched
the references of published systematic reviews, which were identified
with the same electronic databases and the Cochrane library. Titles and
abstracts of potentially eligible studies were retrieved in the Pubmed.
Third, we sought randomised controlled trials (RCTs) in trial registration
websites with the keywords (“new generation”, “second generation,” or
“atypical”) and “antipsychotic”. Finally, we searched the databases of the
Dutch Medicines Evaluation Board and the FDA for unpublished trials.
If studies seemed potentially eligible given title and abstract, full
articles of published studies were retrieved as well as online protocols
of unpublished studies. Two reviewers (T. A. H. and H. J. L.) reviewed
these articles for definitive eligibility. Randomized placebo‐controlled
trials that reported the effect of orally administered atypical antipsy-
chotics on NPS or mortality in participants with Alzheimer's disease or
vascular dementia were included. Studies in patients with Lewy body
or Parkinson's dementia were excluded, because they are much less tol-
erant for antipsychotics, as were studies with multiple drugs in one
intervention arm. There were no restrictionswith respect to publication
date, language, flexible, or fixed dosing of the active treatment and
duration of the study. The search was last rerun in August 2017.2.2 | Data extraction
Two reviewers (T. A. H. and H. J. L.) independently extracted data from
the included studies. First, we extracted general study characteristics:
setting, type of dementia, comparison groups, study duration, number
of randomized patients in each treatment group, and publication status
(published full article, or unpublished) and commercial funding. We
assessed the randomization procedures consisting of the random
sequence generation and allocation concealment, defined and scored as
having a low, unclear or high risk of bias in accordance with the Cochrane
Risk of Bias assessment tool (Higgins, Altman, & Sterne, 2014). We also
recordedwhether information about baseline characteristics of the treat-
ment group for all randomized patients was presented in a baseline table
in line with CONSORT requirement (Schulz, Altman, & Moher, 2010).
Secondly, we extracted the baseline characteristics of all random-
ized participants in the atypical antipsychotic and placebo groups: mean
age and standard deviation (SD), number of men, number of non‐White
persons, number of vascular/mixed dementia, mean severity of demen-
tia and SD, mean severity of NPS and SD. For severity of dementia, we
used the mean Mini‐Mental State Examination (MMSE) score because
it was the most frequently reported instrument (eTable3). For severity
of NPS, we recorded the reported mean NPI(‐NH), BEHAVE‐AD, BPRS,
BRSD, or neurobehavioral rating scale score. In case of multiple
HULSHOF ET AL. 3 of 10reported generic instruments, we preferred the most commonly
used NPI(‐NH), or otherwise the BEHAVE‐AD. Other potentially
important prognostic baseline characteristics, such as (cardiovascular)
comorbidity, somatic and psychiatric medication use, and EPS were
reported too infrequently to be of use for our analyses (eTable1). When
studies included multiple active medication groups (different dosages
or drugs), an average mean or percentage was calculated for these
groups. If the SD for mean age, MMSE, and NPS was missing, the SD
was imputed with the average SD of the other trials.
Finally, we extracted the clinical outcomes. Efficacy of antipsy-
chotics in dementia is usually measured with a generic instrument for
diverse NPS (e.g., NPI and BEHAVE‐AD) or with an instrument specific
for one type of symptoms such as aggression (CMAI). We preferred the
reported total score of a generic instrument to guarantee the compara-
bility of outcomes across trials, but if it was lacking, we will used the
reported total score of the specific instrument. If multiple generic
instruments were used, we extracted the most commonly reported
(NPI(‐NH) or otherwise BEHAVE‐AD). We extracted the mean change
from baseline to end point with its SD for the active drug and placebo
groups. If the confidence interval, standard error, or p value was
reported, the SD was calculated with this information (Cochrane hand-
book). When multiple dosage or multiple drug groups were included in
a trial, an average change was calculated. We also recorded the num-
ber of patients with EPS and the number of deaths during the trial.
For all extracted information, the published article of a trial was
our primary source. Authors provided additional information at our
request (De Deyn et al., 1999; De Deyn, Jeste, Swanink, Kostic, &
Breder, 2005; Kurlan, Cummings, Raman, & Thal, 2007; Paleacu,
Barak, Mirecky, & Mazeh, 2008; Schneider et al., 2006) and meta‐
analyses published by industry were our secondary source. Other
articles and meta‐analyses were our tertiary source of information
(Ballard, Waite, & Birks, 2006; Carson, McDonagh, & Peterson,
2006; Cheung & Stapelberg, 2011; Lee et al., 2004; Lonergan,
Luxenberg, Colford, & Birks, 2010; Maher et al., 2011; Schneider,
Dagerman, & Insel, 2006; Seitz et al., 2013). The reviewers discussed
the differences in the extracted data until consensus was reached.2.3 | Statistical analyses
First, we plotted the difference between group sizes (drug vs. placebo)
against total trial size for 17 trials with unrestricted randomization
(eTable1), and the expected distributions for the 50% and 95% prediction
intervals (Schulz, Chalmers, Grimes, & Altman, 1994). For trials with more
than two active drug groups, we used the first reported active drug group
(and a total trial size of placebo group plus first active drug group). For
studies that used a randomization ratio other than 1:1 for placebo versus
active drug group, we recalculated the size of the active drug group by
dividing the true size by the inverse of the ratio, and then recalculated
the hence found difference back to the original total trial size. We then
plotted this difference against to the true total number of participants. Tri-
als that reported blocked randomization were excluded from this analysis.
Second, we described the range and direction of the baseline
imbalances for studies with and without haloperidol groups. The ratio-
nale for this distinction is that studies with a haloperidol group seemto suggest higher efficacy, lower risk of EPS, and lower risk of mortal-
ity than trials without a haloperidol group (see eFigure 1–3). We then
computed a one‐sided sign‐test per characteristic to test whether the
proportion of studies that reported an imbalance in the most common
direction (e.g., higher mean age in antipsychotic vs. placebo group) was
higher than can be expected by chance (50%). Studies that reported
no difference between groups (e.g., same mean age, which could be
due to rounding) and studies with a missing baseline difference are
automatically discarded from a sign‐test.
Third, we performed meta‐analyses to calculate the pooled mean
difference (MD) for baseline age, severity of dementia and severity of
NPS, and the pooled odds ratio (OR) for men, non‐White persons, and
vascular/mixed dementia with fixed‐effects models (Clark, Fairhurst,
Cook, & Torgerson, 2015; Ebell, 2013; Trowman et al., 2007). We
expected a common effect estimate of zero in these mean baseline
variables. Again, we distinguished between studies with and without
haloperidol groups. The analyses generate an I2‐statistic for heteroge-
neity. We calculated 95% confidence intervals around I2 with the
direct command heterogi in Stata.
Fourth, we performed a meta‐regression analyses to assess the
relationship of the individual baseline imbalances for all randomized
patients with reduction in NPS, risk of EPS, and risk of mortality. The
beta‐coefficients (betas)were calculatedwith 95%confidence intervals.
We estimated the standardizedmean differences (SMD) for NPS reduc-
tion and OR for risk of EPS and mortality. As many trials reported no
deaths in one or both treatment groups, we used the Mantel–Haenszel
weighted fixed effects model with continuity correction based on the
reciprocal of the opposite group arm size to calculate the pooled ORs
(Sweeting, Sutton, & Lambert, 2004). A fixed‐effects model was applied
when heterogeneity (I2) was found to be below 40%, otherwise a
random‐effects model (DerSimonian and Laird model with the estimate
of heterogeneity being taken from the from the Mantel–Haenszel
model) (Deeks, Higgins, & Altman, 2011). The plot of group size differ-
ence against total trial sizewasmade in R (R CoreTeam, 2013), the other
analyses were performed with Stata version 14.1 (StataCorp., 2013).
When we found that a large number of baseline differences were
not reported, we decided to pool the outcomes of studies reporting
and not reporting a baseline characteristic in a post hoc analysis. Given
the discrepancy in results of trials with and without haloperidol group,
this analysis was restricted to the latter type of trials.3 | RESULTS
Our search yielded 1,997 potentially relevant RCTs (Figure 1). We
obtained the reports of 29 RCTs for full text review and finally identi-
fied 23 eligible RCTs with 5,853 participants (Allain et al., 2000;
Brodaty et al., 2003; De Deyn et al., 2004, 1999; Deberdt et al.,
2005; Herz, Volicer, Frankenburg, Colon, & Kittur, 2002; ILO522,
2002; Katz et al., 1999; Kennedy et al., 2005; Mintzer et al., 2006;
Mintzer, Tune, Breder, Swanink, & Marcus, 2007; Paleacu et al.,
2008; RIS‐BEL‐14, 1997; RIS‐INT‐83, 1997; Satterlee, 1995;
Schneider, Tariot, et al., 2006; Street et al., 2000; Streim, Porsteinsson,
Breder, Swanink, & Marcus, 2008; Tariot et al., 2006; Zhong et al.,
2007; ZIP‐128‐105, 1993). Five trials were relatively small and
FIGURE 1 Flow diagram of literature search and study selection











range in mg/d Publishedb
ZIP‐128‐105, 1993 Ziprasidone Nursing home AD‐VAS 23 4 2–6 No
Satterlee, 1995 Olanzapine Nursing home AD 238 8 1–8 No
Ris‐Bel‐14, 1997a Risperidone NR AD 39 4 1–4 No
Ris‐Int‐83, 1997a Risperidone NR AD 18 8 0.5–1.5 No
De Deyn, 1999 Risperidone
Haloperidol
Nursing home AD‐VAS‐MIX 344 12 0.5–4
0.5–4
Yes





AD‐VAS‐MIX 306 3 100–300
2–6
Yes
Street, 2000 Olanzapine Nursing home AD 206 6 5, 10, 15c Yes
Herz, 2002 Risperidone
Olanzapine
NR AD 29 10 0.5–4
2.5–20
No
ILO522, 2002 Iloperidone NR AD‐VAS‐MIX 15 4 0.5–6 No
Brodaty, 2003 Risperidone Nursing home AD‐VAS‐MIX 345 12 0.25–2 Yes
De Deyn, 2004 Olanzapine Nursing home AD 652 10 1, 2.5, 5, 7.5c Yes
Ballard, 2005 Quetiapine Nursing home AD 62 6 50–100 Yes





AD‐VAS‐MIX 494 10 0.5–2
2.5–10
Yes
Kennedy, 2005 Olanzapine Outpatients AD (no NPS) 268 26 2.5–7.5 Yes










Nursing home AD 284 10 25–600
0.5–12
Yes
Mintzer, 2007 Aripiprazole Nursing home AD 487 10 2, 5, 10c Yes
Zhong, 2007 Quetiapine Nursing home AD‐VAS 333 10 100, 200c Yes
Paleacu, 2008 Quetiapine NR AD 40 6 75–300 Yes
Streim, 2008 Aripiprazole Nursing home AD 256 10 0.7–15 Yes
Note. AD: Alzheimer disease; NPS: neuropsychiatric symptoms; NR: not reported; VAS: vascular dementia; Mix; mixed dementia.
amortality data were published in Haupt, 2006(Haupt, Cruz‐Jentoft, & Jeste, 2006).
bTrial with conference abstracts only were considered as unpublished.
cGroups.
dDoctors were allowed to stop medication if deemed inefficient or causing too much side‐effects.
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HULSHOF ET AL. 5 of 10unpublished (Herz et al., 2002; ILO522, 2002; RIS‐BEL‐14, 1997; RIS‐
INT‐83, 1997; ZIP‐128‐105, 1993; Table 1). Twenty trials investigated
one atypical antipsychotic drug, three of which included an extra
haloperidol group, (Allain et al., 2000; De Deyn et al., 1999; Tariot
et al., 2006) and three trials investigated multiple atypical drugs. The
follow‐up was ≤12 weeks in 22 trials, and ≥26 weeks in two trials.
All trials were sponsored completely or partly by industry; one trial
did not report the source of funding (Herz et al., 2002).
No study described the randomization procedure completely in
terms of both the random sequence generation and allocation con-
cealment (eTable 1 and eTable 2). Baseline characteristics were also
poorly reported. Only 13 studies presented a baseline table or baseline
information in the text for all randomized patients, two studies for a
selection of all randomized patients, and eight studies, including
four published studies, did not present a baseline table or baselineFIGURE 2 Treatment versus control group size differences and total
trial size for 17 unrestricted trials, with expected distributions for 50%
and 95% (dotted) prediction intervals









Age in years, mean 17/23 −1.9 to 2.0
Male gender, % 15/21f −9.7 to 4.4
Non‐White race, % 13/21f −4.9 to 3.1
Vascular or mixed dementia, % 5/13 −3.3 to 2.7
MMSE, meanb 8/23 −1.2 to 0.7
NPS, standardized meanc 5/22f −0.146 to 0.271
Note. IPD: individual patient data; MMSE: mini‐mental state examination; NPS:
athe baseline difference for each trial was calculated as the mean or percentag
placebo group.
bMMSE can be scored between 0 and 30; higher is better.
cNPS were measured with different instruments in the studies and therefore th
dn‐ stands for the number of trials with a negative baseline imbalance (f.i. lower
with no baseline imbalance (f.i. similar mean age in antipsychotic and placebo
higher age in antipsychotic versus placebo group).
eone‐sided sign‐test per characteristic to test whether the proportion of studies
could be attributed to chance.
fless than 23, because two trials were performed in men only, two trials in Wh
trial in patients without NPS.information in the text (Etable3). Only three trials reported all six
patients characteristics. The first author of two trials provided
additional data (De Deyn et al., 2005, 1999). For another trial, we
calculated the missing baseline information with the provided IPD
(Paleacu et al., 2008).
Figure 2 presents the relation between the difference between
group sizes (placebo vs. active) and the total sample size for 17 trials
with unrestricted randomization, together with the expected distribu-
tions for the 50% and 95% prediction intervals. Less than expected
trials were outside the 50% and 95% distribution lines, four (24%)
and zero (0%) respectively.
Table 2 shows the range of the actual differences between the
placebo and treatment groups for each of the baseline characteristics.
The percentage men and vascular/mixed dementia showed imbalances
ranging from −9.7% to 4.4% and −9.9% to 2.7% respectively. One trial
showed a difference in NPS of 0.271. Baseline imbalances that we
investigated were not accounted for in the analyses of all but two
trials (Kurlan et al., 2007; Schneider, Tariot, et al., 2006).
Table 2 also shows the direction of the baseline imbalances. No
statistical differences were found. When there was no haloperidol
group, there were numerically more trials with a higher age in the
antipsychotics versus placebo group (8 vs. 2; p = 0.055), with a
higher percentage of men (7 vs. 5; p = 0.387) and a higher percentage
of vascular/mixed dementia (8 vs. 3; p = 0.113). When combining
all trials, the number of trials with a positive versus negative direction
was numerically higher for age (9 vs. 3; p = 0.073) and men (10 vs. 5;
p = 0.125), and lower for severity of NPS (1 vs. 4; p = 0.188).
Table 3 presents the size and heterogeneity of the pooled base-
line differences. The pooled imbalance in the percentage of men in
the trials with a haloperidol group stood out numerically (5.4%), but
none of the imbalances were statistically significantly different. Four
of six baseline characteristics exhibited heterogeneity, when therentipsychotic and placebo groups















2/4/8 0.055 −2.0 to 1.7 1/1/1 0.750 0.073
5/0/7 0.387 2.3 to 7.3 0/0/3 0.125 0.151
3/0/8 0.113 −0.9 to −0.0 2/0/0 0.250 0.291
1/0/3 0.313 −9.9 (1 trial) 1/0/0 0.500 0.500
2/1/4 0.344 −0.2 (1 trial) 1/0/0 0.500 0.500
2/0/1 0.500 −0.126 to −0.048 2/0/0 0.250 0s.188
neuropsychiatric symptoms.
e in the atypical antipsychotic group minus the mean or percentage of the
e mean was standardized with the SD; higher is worse.
age in antipsychotic versus placebo group), and n0 for the number of trials
group), n + for the number of trials with a positive baseline imbalance (f.i.
that reported an imbalance in the direction (in the most common direction)
ite persons only, 10 trials in patients with Alzheimer disease only, and one
TABLE 3 Pooled baseline difference and heterogeneity in atypical antipsychotic versus placebo groups
Trials without haloperidol group Trials with haloperidol group All trials
Patient characteristic
Pooled difference
(95% CI) I2, % (95% CI)
Pooled difference
(95%CI) I2, % (95% CI)
Pooled difference
(95% CI) I2, % (95% CI)
Age in years, mean 0.1 (−0.4; 0.6) 0 (0–55) −0.2 (−1.3; 1.0) 70 (0–91) 0.1 (−0.4; 0.5) 12 (0–49)
Male gender, % 0.3 (−2.8; 3.4) 0 (0–58) 5.4 (−1.9; 12.7) 0 (0–90) 1.1 (−1.8; 3.9) 0 (0–54)
Non‐White race, % −0.1 (−2.5; 2.3) 0 (0–60) −0.5 (−2.3; 2.0) 0 (nt) −0.1 (−2.3; 2.0) 0 (0–57)
Vascular or mixed dementia, % 0.3 (−3.7; 4.2) 0 (0–85) −9.9 (−21.8; 2.0) nt (nt) −1.0 (−4.8; 2.7) 12 (0–82)
MMSE, meana 0.1 (−0.4; 0.5) 9 (0–71) −0.2 (−1.6; 1.2) nt (nt) 0.0 (−0.4; 0.5) 5 (0–68)
NPS, standardized meanb −0.120 (−.252; .011) 27 (0–92) 0.013 (−.178; .205) 0 (nt) −0.077 (−.186; .031) 11 (0–81)
Note. CI: confidence interval; MMSE: mini‐mental state examination; NPS: neuropsychiatric symptoms; nt: not testable (too few studies).
aMMSE can be scored between 0 and 30; higher is better.
bNPS were measured with different instruments in the studies and therefore the mean was standardized with the SD; higher worse.
6 of 10 HULSHOF ET AL.should have been none. Heterogeneity was 70% for the baseline
difference in age in the trials with haloperidol group, and 27% for
the difference in severity of NPS in trials without haloperidol group.
None of the confidence intervals around I2 suggested statistically sig-
nificant heterogeneity.
Table 4 presents the associations between individual baseline
imbalances and the clinical outcomes. Only for age, sex, and race were
there more than 10 trials, the minimum for a reliable meta‐regression
analysis. A higher mean age, a higher percentage of men, and of
persons of non‐White race in the atypical antipsychotic drug than
the placebo group, which was more often the case than not (see
Table 2), was associated with greater efficacy and lower risk of EPS.
In particular, one percentage more males in the treatment versus
placebo group was statistically significantly associated with a higher
reduction in NPS (beta −0.027; 95% CI [−0.047, −0.006]), and one
percentage more non‐White persons with a lower risk of EPS
(beta −0.4; 95% CI [−0.8, −0.1]). An association with mortality risk
could be not confirmed for any of the baseline imbalances.
As half of the baseline imbalances we wanted to abstract were
not reported, we pooled the clinical outcomes for trials with and
without missing baseline information for each baseline characteristic.
Efficacy was consistently higher and risk of EPS consistently lower in
studies without baseline information than for studies with this
information (Table 5). Risk of mortality was, however, lower in studies
with missing age, sex, and type of dementia, but higher in studies with
missing race, MMSE, and severity of NPS.TABLE 4 Relationship of individual baseline imbalances with efficacy an
Imbalance between atypical
antipsychotic and placebo group
Efficacy Change in
SMDa (95% CI)
Age in years, mean −0.046 (−0.123; 0.030)
Male gender, % −0.027 (−0.048; −0.006)
Non‐White race, % −0.013 (−0.049; 0.023)
Vascular or mixed dementia, %b 0.015 (−0.011; 0.040)
MMSE, meanb −0.116 (−0.299; 0.067)
NPS, standardized meanb 0.109 (−2.093; 2.311)
Note. CI: confidence interval; EPS: extrapyramidal symptoms; MMSE: mini‐me
SMD: standardized mean differences.
aper unit increase in the baseline difference.
bresults based on less than 10 trials.4 | DISCUSSION
We reviewed the randomization procedures and baseline imbalances
of 23 randomized placebo‐controlled trials of atypical antipsychotics
in 5,853 patients with dementia. All trials reported the randomization
procedures incompletely, and only three trials reported the six base-
line characteristics of interest for all randomized patients. Numerically
more trials reported a higher mean age and a higher percentage of
men and of non‐White persons in the atypical antipsychotics group
than in the placebo group. These imbalances were associated with
greater efficacy and lower risk of EPS, but not with risk of mortality.
Trials with missing baseline information seemed to have a more favor-
able pooled efficacy and lower risk of EPS than trials that reported this
information.4.1 | Randomization procedures
The goal of random sequence generation and concealment of
allocation is that investigators, physicians, and patients cannot foresee
allocation and then change the decision or time to enroll, or change
the allocation itself. If executed correctly, randomization will distribute
measured and unmeasured prognostic patient characteristics ran-
domly between groups, hence reducing bias, so that the difference
in outcome can be interpreted as an effect of treatment. Baseline





−0.0 (−0.7; 0.7) 0.4 (−0.9; 1.6)
−0.1 (−0.3; 0.1) −0.2 (−0.5; 0.1)
−0.4 (−0.8; −0.1) −0.1 (−0.6; 0.4)
−0.1 (−0.3; 0.4) 0.2 (−0.4; 0.7)
0.9 (−2.7; 4.5) −1.0 (−4.0; 2.1)
−7.9 (−30.0; 14.2) 2.7 (−9.4; 14.7)
ntal state examination; NPS: neuropsychiatric symptoms; OR: odds ratio;
TABLE 5 Pooled efficacy, risk of EPS and risk of mortality for trials with reported and missing baseline informationa
Baseline characteristic
Efficacy EPS Mortality
SMD (95% CI) OR (95% CI) OR (95% CI)
Age in years, mean Reported (12) −0.102 (−0.173; −0.031) Reported (11) 1.7 (1.3; 2.2) Reported (14) 1.7 (1.1; 2.6)
Missing (2) −0.243 (−0.390; −0.095) Missing (1) 1.6 (0.9; 2.7) Missing (6) 1.5 (0.6; 3.4)
Male gender, % Reported/NA (11) −0.100 (−0.172; −0.028) Reported/NA (10) 1.8 (1.3; 2.3) Reported/NA (14) 1.7 (1.1; 2.6)
Missing (3) −0.243 (−0.387; −0.100) Missing (2) 1.3 (0.8; 2.2) Missing (6) 1.5 (0.6; 3.3)
Non‐White race, % Reported/NA (10) −0.107 (−0.176; −0.038) Reported/NA (9) 1.8 (1.3; 2.3) Reported/NA (12) 1.6 (1.1; 2.5)
Missing (4) −0.260 (−0.430; −0.090) Missing (3) 1.4 (0.8; 2.2) Missing (8) 1.8 (0.8; 4.4)
Vascular or mixed dementia, %b Reported/NA (13) −0.107 (−0.174; −0.040) Reported/NA (11) 1.7 (1.3; 2.2) Reported/NA (19) 1.7 (1.1; 2.5)
Missing (1) −0.383 (−0.611; −0.155) Missing (1) 1.6 (0.9; 2.7) Missing (1) 1.5 (0.4; 5.4)
MMSE, mean Reported (6) −0.079 (−0.174; 0.016) Reported (5) 2.0 (1.4; 2.8) Reported (7) 1.6 (0.9; 2.9)
Missing (8) −0.171 (−0.257; −0.084) Missing (7) 1.3 (0.9; 1.9) Missing (13) 1.7 (1.0; 2.8)
NPS, standardized mean Reported/NA (3) −0.042 (−0.181; 0.097) Reported/NA (3) 2.4 (1.3; 4.5) Reported/NA (4) 1.2 (0.5; 2.6)
Missing (11) −0.152 (−0.225; −0.080) Missing (9) 1.5 (1.2; 2.0) Missing (16) 1.8 (1.2; 2.8)
Note. CI: confidence interval; EPS: extrapyramidal symptoms; MMSE: mini‐mental state examination; OR: odds ratio; SMD: standardized mean differences;
NA: not applicable, because some trials were performed in men only, in White persons only, in patients with Alzheimer disease only, and in patients without
NPS at baseline.
aonly trials without an extra haloperidol group.
banalyses performed with random effects models.
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occur, but in general, the larger the sample size of an individual trial
and the larger the number of trials in a review, the smaller the baseline
imbalances can expected to be.
This is one of few studies that used objective measures to address
risk of bias because of baseline imbalances in trials. Assessments of
randomization are usually limited to the procedures, and these
assessments can vary widely (Savovic et al., 2014).For example, using
the Cochrane assessment tool, we found that 22 trials had an
unclear random sequence generation and 22 trials an unclear
concealment of allocation. In contrast, a Cochrane review reported
that only four trials had unclear concealment of allocation
(Ballard et al., 2006). Yet another review found that 100% of trials
scored “high quality” on the Jadad and Van Tulder scale, and 90% on
the Brown scale (Ma et al., 2014). We compared the true with
expected group size difference and found that the distribution of
differences was substantially smaller than could be expected by
chance: 76% instead of 50% of the differences fell inside the 50%
prediction interval.4.2 | Baseline imbalances
CONSORT requires trial articles to present baseline tables for all ran-
domized patients. We found four published trials that did not present
a baseline table at all. Only a limited number of trials reported the six
baseline characteristics we studied. Other characteristics that are
likely to predict efficacy or adverse events, such as comorbidity and
medication use, were also missing in many articles. Baseline informa-
tion might not have been missing at random either. In our study, we
found that trials with missing information had a more favorable pooled
efficacy and risk of EPS than trials that provided the baseline informa-
tion for each of the six characteristics. Selective reporting is a common
problem in the medical scientific literature (Higgins et al., 2014), and
missing information on prognostic baseline characteristics might be
another example.In the articles with baseline information, most of the imbalances
seemed small but some were large and obviously clinically relevant.
For example, in one study 30% of the participants receiving risperi-
done had vascular/mixed dementia versus 41% of the placebo group
(De Deyn et al., 1999). The baseline imbalances that we investigated
were not accounted for in the analyses of all but two trials
(Kurlan et al., 2007; Schneider, Tariot, et al., 2006).
Our next step was to pool the baseline differences and assess
heterogeneity, a method recently developed to quantify baseline
differences (Clark et al., 2014, 2015). None of the pooled baseline
differences we studied were statistically significant from zero. Some
baseline differences showed considerable heterogeneity: The differ-
ence in mean age in trials with a haloperidol group (70%) and that in
severity of NPS in trials without haloperidol group (27%). Heterogene-
ity for three characteristics was slight (between 5% and 11%). Perhaps,
this amount of heterogeneity in baseline imbalances could be consid-
ered substantial as well, given that minimal heterogeneity is expected
with an appropriate randomization design and conduct.
To quantify baseline imbalances, we also studied whether a posi-
tive or negative direction was more common. We found that numeri-
cally more trials reporting a higher mean age, higher percentage of
men and lower severity of NPS, the primary focus of treatment in
the trials, in the atypical antipsychotics group than in the placebo
group. Others have suggested that imbalances in age and the primary
outcome at baseline could be a good start when studying baseline
imbalances.2 We would like to add baseline imbalance in sex, and also
differentiate between trials with and without a treatment arm with the
old (patent free) competitor drug.4.3 | Clinical outcomes
After assessing the presence of baseline imbalances, we investigated
whether they might have affected the clinical outcomes of the trials.
We found that higher mean age, higher percentage of men, and higher
percentage of non‐White persons at baseline in the antipsychotic than
8 of 10 HULSHOF ET AL.the placebo group was associated with higher efficacy. For the base-
line imbalance in sex, this was a statistically significant effect. Higher
mean age, higher percentage of men, and higher percentage of non‐
White persons at baseline was also associated with a lower risk of
EPS. For the baseline imbalance in race, this was a statistically signifi-
cant effect. The effect of the baseline differences on risk of mortality
was not so consistent but this was not a targeted outcome either. To
our knowledge, there are no other studies that used this approach.
In addition, we found a consistent pattern of studies with missing
baseline information having more favorable efficacy results and a
lower risk of EPS on average. Naturally, the same studies with missing
information having been pooled for each of the six baseline character-
istics might partly underlie this finding. Again, the pattern was not
consistent for the risk of mortality.4.4 | Strengths and limitations
This is one of few studies that quantified baseline imbalances in trials.
In addition, we performed an extensive literature search to identify
unpublished studies. We hypothesized that baseline imbalances were
related to outcomes, and hence the imbalance might depend on the
publication status of a study. We used FDA and EMA databases
among other literature sources (Schroll & Bero, 2015). The result
was that we found six unpublished trials in addition to those included
in previous meta‐analyses (Ma et al., 2014; Schneider et al., 2005). As
these were small studies and some did not report all outcomes,
efficacy, risk of EPS, and risk of mortality for atypical antipsychotics
versus placebo were not substantially different from those published
before (Ma et al., 2014; Schneider et al., 2005).
A limitation of our study is that our analyses depended on the
amount of baseline information provided in the articles. Information
on type of dementia, MMSE, and severity of NPS was often lacking.
Power of our study might have been insufficient to detect relevant
baseline imbalances and associations of these baseline imbalances
with clinical outcomes.5 | CONCLUSION
Despite randomization, placebo‐controlled trials of atypical antipsy-
chotics in dementia show heterogeneous baseline imbalances.
Baseline imbalances that were not taken into account might have
mistakenly led to an overestimated efficacy and underestimated risk
of EPS. Our findings underscore the need for adequate randomization
procedures, and reporting of baseline characteristics for all random-
ized patients per treatment group. In addition, baseline imbalances
need to be assessed objectively as part of systematic reviews.DECLARATION OF INTEREST STATEMENT
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